| 摘要 |
2-Substd. quinoline cpds. of formula (II) and pharmaceutically acceptable salts are new where R1 = H, halogen, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, OR2, SR2, S(O)R2, SO2R2, NR2R3, CHO, COOR2, COR2, -C(OH)(R2)2, CN, NO2, opt. substd. phenyl, opt. substd. benzyl or opt. substd.phenyl, opt. substd. benzyl or opt. substd. phenethyl; R2 = H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, opt. substd. phenyl, opt. substd. benzyl or opt. substd. phenethyl; R3 = H, halogen, NO2, CN, OR2, SR2, N(R2)2 or 1-8C alkyl; CR2R3 may be the radical of a naturally occurring amino acid, R4 = H, halogen, NO2, CN, OR2, SR2, N(R2)2, 1-8C alkyl or COR2, R5 = (CH2)s-C(R6)2-(CH2)s-R7, R6 = H or 1-4C alkyl; R7 = W-R8 or mono- or bicyclic heterocyclic gp. contg. 3-12 ring C and 1 or 2 N, O or S heteroatoms, each ring being 5- or 6-membered; R8 = max. 21C hydrocarbyl or acyl residue of an acyclic or monocyclic carboxylic acid contg. max. heteroatom in the ring; R9=OR10, SR10, or N(R10)2; R10 = H, 1-6C alkyl, -COR11, phenyl or benzyl, or N(R10)2 may form a 5- or 6-membered ring contg. up to 2 N,O or S heteroatoms; R11 = H, 1-8C alkyl, 2-8C alkenyl, 2-8C alknyl, CF3, phenyl, benzyl or phenethyl; R12 = R2 or halogen; m,m'= 0-8; n,n'= 0 or 1; p,p'= 0-8; m+n+p = 1-10; m'+n'+p'= 1-10; s = 0-3; Q1,Q2 = COOR2, tetrazole, COOR5, CONHSO2R11, CM, CON(R10)2, CHO, CH2OH, COCH2OH or NHSO2R11; or if Q1 or Q2 = COOH and R3 = OH, SH or NHR2, then Q1 or Q2 and R3 and the C atoms through which they are attached may form a heterocyclic ring with loss of water; W= O,S or NH; X'= O, S, SO2, NR2 or C(R2)2; X2, X3 = O, S, SO or SO2, Y = -CR2=CR2-, ethynylene, -C(R2)2-X1-, -X1-C(R2)2-, -C(R2)2-X'-C(R2)2-, -CO-, -NR2-CO-, -CO-SR2-, O, S, NR2 or cyclopropanedinyl of formula (a); Z1,Z2 = -CONR2-. |
